The Effect of Omalizumab on Responses to Cat Allergen Challenge
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
This research is being done to study the effects of the drug omalizumab (Xolair) in people
with cat allergies. The investigators will use omalizumab to study changes in the cells in
the nose, skin and blood that cause allergies. The investigators predict that cells in the
blood will be effected before cells in the nose or skin.
Phase:
N/A
Details
Lead Sponsor:
Johns Hopkins University
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)